Jump to any asset
849 assets, updated daily
As of September 15, 2026, Elevance Health, Inc. (ELV) trades at $419.17. CleaRank Financial AI rates it Buy with a fair value of $457.00, 9.0% above the current price. Wall Street's consensus target is $457.00 across 22 analysts. RSI at 62 is in neutral territory, and the price is above its 50-day average of $397.60.
Elevance Health, Inc. (ELV)
Elevance Health, Inc. NYSE
$419.17
-5.070 (-1.20%)
Latest Price
AI Analyst Consensus
70 / 100
Elevance Health, Inc. (ELV) is trading at $419.17, showing strong bullish momentum as it trades above its 50-day and 200-day moving averages ($397.60 and $361.94). The company's recent earnings have shown consistent beats, with the latest quarter to June 2026 exceeding estimates by 19.97%. insiders are net sellers, with total purchases of $5.1 million against $3.7 million in sales, indicating a slight buy signal and institutional conviction. While the company faces near-term revenue growth challenges, with current and next quarter estimates showing a decline of approximately 2.00% year-over-year, its strong performance in earnings and positive insider activity provide a solid foundation. The healthcare sector, in which ELV operates, shows a median revenue growth of 8.1%, highlighting ELV's current underperformance in this metric. However, its profit margin of 2.47% and return on equity of 11.13% are respectable within its industry context.
ELV Price Analysis
Market Metrics
Open
$422.47
Day Range
$415.64 to $423.38
Prev Close
$424.24
Volume
20.6K
52-Week Range
$274.84 to $436.24
Market Cap
$92.00B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a notable discount to sector peers (-41%), which may indicate undervaluation or specific company headwinds.
ELV Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 5 quarters, ELV beat estimates 5 times. However, the stock fell 3 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
ELV Analysis
Company's Health
4/5
12-Month Analyst Target
+9.02% Upside
Median of 22 analysts (12-month)
$457.00
AI Technical Analysis
Elevance Health, Inc. (ELV) is currently trading above its 50-day SMA of $397.60 and its 200-day SMA of $361.94, indicating a bullish trend. The RSI is at 61.77, signaling bullish momentum, and the MACD at 6.20 further supports positive sentiment. The stock is also trading above its 20-day EMA of $406.30. Key support levels are near the 50-day SMA, while resistance is less defined given the upward trajectory. Volume has been significantly below average recently, which warrants monitoring as the stock moves higher. The overall chart structure suggests continued upward potential, supported by the prevailing bullish technical indicators.
ProTips
- Monitor revenue growth trends closely, as the current negative trajectory contrasts with sector averages and could present a headwind.
- Insider net buying activity suggests underlying confidence; consider this as a positive signal for future performance.
- Given the consistent earnings beats, investors may find opportunities around earnings release dates, though recent price reactions warrant caution.
Key Catalysts
Bullish
Consistent Earnings Beats
Elevance Health has a history of exceeding EPS estimates, most recently by 19.97% in the quarter to June 2026, indicating strong operational execution.
Source: Earnings ReportsBullish
Insider Net Buying Activity
Insiders have purchased $5.1 million worth of stock against $3.7 million in sales, signaling a slight buy signal and potential institutional conviction.
Source: Insider TransactionsBearish
Negative Revenue Growth Trend
Current and next quarter revenue estimates show a year-over-year decline of approximately 2.00%, lagging behind the sector's positive growth.
Source: Analyst EstimatesNeutral
Analyst Ratings Maintain Positive Stance
A majority of analysts maintain Buy or Overweight ratings, with a median price target of $457.00, indicating Wall Street's general optimism.
Source: Analyst RatingsMarket Outlook
Elevance Health, Inc. (ELV) is expected to see continued positive performance driven by strong insider selling and consistent earnings beats, with a base case target of $614.96. The company's valuation appears attractive relative to its sector peers, offering a potential upside of 9% to the median analyst target price of $457.00. The primary risks include the current trend of negative revenue growth, which contrasts with sector averages, and potential market reactions to earnings reports despite beats. Upside catalysts could include a reversal in revenue trends or further positive insider selling activity, while downside risks involve persistent revenue contraction or increased competitive pressures within the healthcare insurance market.
Key Statistics
| Market Cap | 92.00B |
|---|---|
| P/E Ratio | 18.76 |
| EPS (TTM) | 22.61 |
| Dividend Yield | 1.64% |
| 52 Week High | 436.24 |
| 52 Week Low | 274.84 |
Elevance Health, Inc. (ELV) trades at a P/E ratio of 18.76, which is below the sector median of 31.9, suggesting a potential valuation discount relative to peers. Its price-to-sales ratio of 0.46 is also lower than the sector average of 3.7. The company's return on equity stands at 11.13%, and its profit margin is 2.47%, with an operating margin of 4.56%. Despite a slight revenue growth of 1.4% compared to the sector median of 8.1%, the company's fundamentals appear sound. The debt-to-equity ratio of 0.69 is within reasonable bounds for the sector. The current valuation metrics suggest that the stock may be undervalued compared to its industry peers, especially considering its consistent earnings beats.
Earnings & Growth Analysis
Elevance Health, Inc. (ELV) has demonstrated a strong track record of exceeding earnings expectations. The most recent quarter to June 2026 saw EPS actual of $7.45 against an estimate of $6.21, a surprise of 19.97%, though the stock price declined by 4.48%. Prior quarters also showed positive surprises, including a 16.37% beat in the quarter to March 2026 and a 32% beat in the quarter to December 2025. This consistent outperformance in earnings suggests operational efficiency and effective cost management.
Key Risks
Near-term revenue growth is a concern, with current and next quarter estimates showing a decline, contrasting with the sector's median growth. While insider buying is a positive signal, the recent price reaction to the latest earnings beat warrants attention, suggesting potential market skepticism or broader sector headwinds. The company's valuation, while attractive on a P/E basis, needs to be monitored against its slower revenue growth compared to peers.
Technical Indicators
| RSI (14) | 61.77 |
|---|---|
| MACD | 6.20 |
| SMA 50 | 397.60 |
| SMA 200 | 361.94 |
RSI
Bullish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($397.60) above the 200-day SMA ($361.94), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.11
Weak correlation
Nasdaq 100 (QQQ)
+0.04
Weak correlation
Bitcoin (BTC)
+0.03
Weak correlation
Gold (XAU)
+0.03
Weak correlation
Check Custom Correlation
How does any other asset move with ELV? One year of daily closes, Pearson correlation.
Try
ELV Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$410.79
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$419.17
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$398.46
MAX LOSS
-3.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (61.8) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$431.33
+5% (Conservative)
+2.9% (Aggressive)
TARGET 2
$451.87
+10% (Conservative)
+7.8% (Aggressive)
TARGET 3
$472.40
+15% (Conservative)
+12.7% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for ELV is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 15, 2026.Growth of $10,000
A $10,000 investment in ELV in September 2016 would be worth about $34,119 today, compared with about $35,344 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ELV today could grow to about $26,070 by 2036 in the base case, with a bull case near $92,933 and a bear case around $7,313. Projections are statistical simulations, not guarantees.
ELV Stock Price Prediction: 2030
CleaRank's simulation projects a price near $615 for ELV by 2030 in the base case, from $419 today (1.5x over 4 years). The downside path ends near $275. These are outcomes of a Monte Carlo simulation run on ELV's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $309 | $461 | $690 |
| 2028 | $288 | $508 | $896 |
| 2029 | $279 | $559 | $1,121 |
| 2030 | $275 | $615 | $1,374 |
| 2031 | $275 | $677 | $1,663 |
| 2032 | $278 | $745 | $1,994 |
| 2033 | $283 | $820 | $2,374 |
| 2034 | $289 | $902 | $2,812 |
| 2035 | $297 | $993 | $3,316 |
| 2036 | $307 | $1,093 | $3,895 |
Method: 10,000 simulated price paths using ELV's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
ELV Insider Trading Analysis
Bought
$5.1M
5 Transactions
Sold
$3.7M
6 Transactions
Insiders
22
Active Traders
Avg Transaction
$795.0K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 22, 2021 | HAYTAIAN PETER D
Officer
|
Sell | 59.5K | $20.8M |
| May 24, 2021 | GALLINA JOHN E
Chief Financial Officer
|
Sell | 46.4K | $18.3M |
| Jul 22, 2024 | BOUDREAUX GAIL A KOZIARA
Chief Executive Officer
|
Sell | 34.0K | $17.0M |
| Apr 24, 2024 | NORWOOD FELICIA F.
Officer
|
Sell | 20.3K | $10.8M |
| Mar 4, 2024 | HAYTAIAN PETER D
Officer
|
Sell | 21.1K | $10.6M |
| Mar 10, 2022 | HAYTAIAN PETER D
Officer
|
Sell | 17.7K | $8.2M |
| Mar 24, 2023 | MCCARTHY GLORIA M
Officer
|
Sell | 15.1K | $6.7M |
| Apr 30, 2020 | ZIELINSKI THOMAS C
General Counsel
|
Sell | 19.3K | $5.4M |
| May 15, 2020 | MCCARTHY GLORIA M
Officer
|
Sell | 18.3K | $5.0M |
| Apr 16, 2020 | MCCARTHY GLORIA M
Officer
|
Sell | 16.9K | $4.6M |
Page 1 of 1
Frequently Asked Questions
What is Elevance Health's stock price forecast for 2030?
Elevance Health's stock price forecast for 2030, based on Monte Carlo simulations, projects a base case of $614.96, with a downside scenario of $275.24 and an upside scenario of $1373.98. These figures represent statistical outcomes, not guaranteed price targets.
Is Elevance Health stock a buy right now?
Elevance Health (ELV) is currently rated as a Buy with a consensus score of 70 out of 100. The stock is trading above key moving averages, showing bullish momentum, and insiders are net sellers, signaling institutional confidence.
What is the consensus rating for Elevance Health?
The consensus rating for Elevance Health is Buy, supported by a consensus score of 70 out of 100. Wall Street analysts have a median price target of $457.00, implying a 9% upside from the current price.
How has Elevance Health performed in recent earnings reports?
Elevance Health has consistently beaten earnings estimates. The latest quarter to June 2026 showed a 19.97% EPS surprise, following a 16.37% beat in the prior quarter. This pattern of earnings outperformance indicates strong operational execution.
What are the key technical indicators for Elevance Health?
Elevance Health is trading above its 50-day and 200-day moving averages ($397.60 and $361.94), with bullish momentum indicated by its RSI at 61.8 and a positive MACD. The stock is also above its 20-day EMA, suggesting a positive short-to-medium term trend.
Are there any significant insider transactions for Elevance Health?
Yes, insiders at Elevance Health have been net buyers, with total purchases of $5.1 million compared to $3.7 million in sales in recent filings. This activity, resulting in a 1.37 buy-sell ratio, suggests a slight buy signal and insider confidence in the company's prospects.
How does Elevance Health compare to its sector averages?
Elevance Health's P/E ratio of 18.76 is below the sector median of 31.9, and its price-to-sales ratio of 0.46 is also lower than the sector average of 3.7. However, its revenue growth of 1.4% lags behind the sector median of 8.1%.